Obesity drugs are advancing with over 100 drugs in development. New treatments combining GLP-1 with other hormones are being developed.

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.